再生元与再鼎医药合作开发REGN1979(CD20xCD3双特异性抗体),治疗非霍奇金淋巴瘤

2020-04-09 MedSci原创 MedSci原创

REGN1979是利用Regeneron双特异性抗体平台开发的新型双特异性单克隆抗体,旨在通过将细胞毒性T细胞(与CD3结合)与淋巴瘤细胞(与CD20结合)连接并激活来杀死肿瘤。

再生元(Regeneron)与再鼎医药(Zai Lab)宣布宣布了一项战略合作,将在中国大陆、香港、台湾和澳门开发和商业化REGN1979(CD20xCD3双特异性抗体)。这项合作将支持REGN1979针对B细胞非霍奇金淋巴瘤(B-NHL)的2期临床。

REGN1979是利用Regeneron双特异性抗体平台开发的新型双特异性单克隆抗体,旨在通过将细胞毒性T细胞(与CD3结合)与淋巴瘤细胞(与CD20结合)连接并激活来杀死肿瘤。

根据该协议的条款,Regeneron将获得3000万美元的预付款,并有资格获得高达1.6亿美元的额外监管和销售里程碑。在某些试验中,Zai Lab将负担REGN1979的全球开发费用,并将获得在中国大陆、香港、台湾和澳门开发和独家商业化REGN1979肿瘤学的权利。

REGN1979被美国食品和药物管理局(FDA)授予孤儿药指定,用于治疗滤泡性淋巴瘤(FL)和弥漫性大B细胞淋巴瘤(DLBCL)。REGN1979目前正在进行一项1期试验以及潜在的2期试验用于治疗FL、DLBCL和其他淋巴瘤晚期。

原始出处:

https://www.firstwordpharma.com/node/1714122?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-05-12 aliceclz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-12 研发小兵

    双特异性抗体是热点,但是也不一定都有效!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-11 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1899369, encodeId=22f41899369c7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Nov 09 06:31:41 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943803, encodeId=04f919438034d, content=<a href='/topic/show?id=44ca428e60' target=_blank style='color:#2F92EE;'>#CD20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4287, encryptionId=44ca428e60, topicName=CD20)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Tue May 12 02:31:41 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1025807, encodeId=82dd102580ece, content=双特异性抗体是热点,但是也不一定都有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=研发小兵, createdTime=Sun Apr 12 11:31:41 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1389625, encodeId=a81e1389625e5, content=<a href='/topic/show?id=226d30e1046' target=_blank style='color:#2F92EE;'>#再鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30710, encryptionId=226d30e1046, topicName=再鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI5PdY90y5Jib8FnPhCXTR2d9v3K17epNSwB2eb0vmXUldNJl2e72S4unZTAHLAojicdVSialTDFHAxA/132, createdBy=78d82500042, createdName=ms7514935887898259, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410006, encodeId=481814100063f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526466, encodeId=11e61526466ec, content=<a href='/topic/show?id=1e416e954c3' target=_blank style='color:#2F92EE;'>#特异性抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67954, encryptionId=1e416e954c3, topicName=特异性抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8b711724149, createdName=hyf032, createdTime=Sat Apr 11 02:31:41 CST 2020, time=2020-04-11, status=1, ipAttribution=)]

相关资讯

前阿斯利康副总裁梁怡去向再鼎医药,外资高管纷纷回流国内创新药企

就在前不久,阿斯利康全球执行副总裁、国际业务及中国总裁王磊向员工正式宣布了梁怡将于6月1日离任的消息。而在今天,梁怡的最终去向也定了,也是国内一家创新型生物药企,再鼎医药。   01 不变的是坚持 前阿斯利康中国副总裁、肿瘤事业部负责人梁怡 ▌超过20年肿瘤领域经验 梁怡拥有复旦大学临床医学学士学位和中欧国际工商学院EMBA(高级工商

再鼎医药香港上市肿瘤电场治疗产品Optune

再鼎医药(纳斯达克股票代码:ZLAB)今天宣布,用于多形性胶质母细胞瘤(GBM)的肿瘤治疗电场Optune已经正式登陆香港并惠及首位患者。再鼎医药今天宣布,用于多形性胶质母细胞瘤(GBM)的肿瘤治疗电场Optune已经正式登陆香港并惠及首位患者。香港是继美国,欧洲和日本之后第四个上市该治疗方案的市场。Optune也是继治疗卵巢癌的PARP抑制剂则乐(尼拉帕利)后再鼎医药上市的第二款产品。作为一种全

喜讯!陈列平教授加入再鼎医药科学顾问委员会

再鼎医药今日宣布,聘请肿瘤免疫疗法先驱陈列平教授为公司科学顾问委员会成员,为再鼎医药不断发展的抗肿瘤新药自主研发方向和项目,特别是在肿瘤免疫方面,提供建议及指导。 再鼎医药董事长兼首席执行官杜莹博士表示: “我们非常荣幸像陈列平教授这样的肿瘤免疫学家可以加入再鼎医药的科学顾问委员会。作为免疫肿瘤研究的先驱,陈教授在肿瘤免疫方面的研究尤其是PD-1/PD-L1抗体方面的发现为肿瘤

中国新锐公司再鼎医药 正式申请赴美上市

昨日,中国生物技术新锐再鼎医药(Zai Lab)正式申请赴美上市,并计划登陆纳斯达克市场(Nasdaq),募资1.15亿美元。消息一经确认,得到了业内的广泛关注。

再鼎医药获得美国生物公司MacroGenics三款在研产品的中国区域开发及商业化**授权

11月29日,位于张江科学城的再鼎医药与专注于创新单克隆抗体研发的美国生物医药公司MacroGenics就三个免疫肿瘤产品达成独家合作。

肿瘤电场治疗在港上市,胶质母细胞瘤迎十年来突破性疗法

今日(2月28日),再鼎医药宣布,首款肿瘤电场治疗产品Optune®在香港正式上市。肿瘤电场治疗是一种利用特定电场频率干扰细胞分裂,抑制肿瘤增长并使受电场影响的癌细胞死亡的治疗方案。Optune®作为全球首个且唯一经美国FDA批准的肿瘤电场治疗产品,已在美国、欧洲、日本及其他多个国家及地区获批用于胶质母细胞瘤的治疗,同时其他多项应用于实体肿瘤适应症的临床试验也在同步进行。肿瘤电场治疗为胶质母细胞瘤